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Abstract
Induced pluripotent stem (iPS) cells are at the forefront of research in regenerative medicine
and are envisaged as a source for personalized tissue repair and cell replacement therapy.
Here, we demonstrate for the first time that oligodendrocyte progenitors (OPs) can be de-
rived from iPS cells generated using either an episomal, non-integrating plasmid approach
or standard integrating retroviruses that survive and differentiate into mature oligodendro-
cytes after early transplantation into the injured spinal cord. The efficiency of OP differentia-
tion in all 3 lines tested ranged from 40% to 60% of total cells, comparable to those derived
from human embryonic stem cells. iPS cell lines derived using episomal vectors or retrovi-
ruses generated a similar number of early neural progenitors and glial progenitors while the
episomal plasmid-derived iPS line generated more OPs expressing late markers O1 and
RIP. Moreover, we discovered that iPS-derived OPs (iPS-OPs) engrafted 24 hours follow-
ing a moderate contusive spinal cord injury (SCI) in rats survived for approximately two
months and that more than 70% of the transplanted cells differentiated into mature oligo-
dendrocytes that expressed myelin associated proteins. Transplanted OPs resulted in a sig-
nificant increase in the number of myelinated axons in animals that received a
transplantation 24 h after injury. In addition, nearly a 5-fold reduction in cavity size and
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reduced glial scarring was seen in iPS-treated groups compared to the control group, which
was injected with heat-killed iPS-OPs. Although further investigation is needed to under-
stand the mechanisms involved, these results provide evidence that patient-specific, iPS-
derived OPs can survive for three months and improve behavioral assessment (BBB) after
acute transplantation into SCI. This is significant as determining the time in which stem cells
are injected after SCI may influence their survival and differentiation capacity.
Introduction
Since the discovery of induced pluripotent stem (iPS) cells, the field of regenerative medicine
has grown exponentially, and the feasibility of ‘adult cell-derived’ therapy is emerging. One of
the main goals of iPS cell research is the derivation of stem cell lines that can be used to replace
diseased or damaged tissues without generating a significant host immune response or relying
on embryonic sources of cells [1–3]. A highly promising study by Wang et al. showed that
human iPS OPs survived as long as 9 months following tissue grafts in the brains of shiverer
mice, robustly myelinating axons and substantially increasing the survival rate of the mice [4].
However, the optimism regarding the use of iPS cells is tempered by concerns regarding their
effectiveness for specific therapies, such as spinal cord injury (SCI).
A number of studies have investigated transplantation of oligodendrocyte progenitors
(OPs) derived from human embryonic stem (ES) cells or mesenchymal stem cells (MSCs) in
animal models of SCI, with some conflicting results. Previously, Yoshihara et al. reported that
after transplantation of MSC in rats with SCI, there was no correlation between cell survival
and locomotor improvement [5]. Yet more recently, Torres and Espín et al. published a prom-
ising study in which acutely grafted mesenchymal stromal cells in rat SCI led to improved loco-
motion [6]. Injections of bone marrow-derived MSCs have also been shown to improve
hindlimb locomotion, reduce cavity area, and reduce inflammation in rats [7–9] and to im-
prove recovery of the panniculus reflex and diminish pain responses in dogs with SCI [10].
The contradictions in the results of these studies include not only the efficiency of OP differ-
entiation but also the time at which these cells are transplanted after injury. For instance, most
studies have performed cell transplants one week or more after injury, after which the initial
trauma to the spinal cord has already been compounded by secondary injury mechanisms, in-
cluding glial scarring and cavitation at the injury epicenter [11,12]. The alternative is to per-
form acute transplantation of cells immediately following the injury. However, a concern for
early cell transplantation of OPs is that the injured spinal cord environment would either kill
or inhibit the differentiation of transplanted OPs. Given emerging evidence that progenitor
cells respond to stress stimuli to facilitate tissue regeneration [13], it seems reasonable that
OPs, unlike more mature cells, can survive the oxidative and immunological stresses of the in-
jured spinal cord and that this may help facilitate their differentiation.
In similar fashion, early transplant studies with neural stem cells have demonstrated the
ability of these progenitor cells to survive the hostile injured SCI environment and to provide
neuroprotective effects that reduce secondary degeneration and preserve neuronal and oligo-
dendrocyte survival [14–16]. For instance, work by Teng et al., demonstrates that animals im-
planted with a scaffold containing neural stem cells (NSCs) in hemisectioned spinal cords
results in long-term improvements in motor function, related to a reduction of secondary de-
generation, and the ability of NSCs to antagonize excitotoxic mechanisms [16]. Similar results
were shown by human embryonic germ cell-derived embryoid body (EB)-derived cells in a
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virus-induced motor neuron disease model when EB-derived cells transplanted into the lumbar
cerebrospinal fluid migrated to the damaged tissue and reduced motor neuron death [17].
Acute transplantation of MSC into injured spinal cord has also shown improved outcomes [6].
Recently, it was shown that a combined therapy of MSC-NSC intravenous injection immedi-
ately following SCI in rats lead to improved locomotion 6 weeks after injury, although there
was no evidence of MSC survival beyond 2 weeks [18]. Studies directly compared early and de-
layed transplantation of MSCs have also revealed that only early-grafted cells improved loco-
motion and electrophysiological outcomes post-injury, although MSC grafts did not survive
past 2 weeks [6]. Our group has also shown similar improvements using ES-derived OPs and
extends this approach to iPS-derived OPs [19]. Thus, we hypothesized that iPS-OPs trans-
planted within 24 hours of injury can survive implantation, differentiate into mature oligoden-
drocytes, and integrate into the injured spinal cord.
This study is the first to describe how early transplantation of iPS-OPs is feasible for three
independent iPS-derived cell lines, including two generated by integrating retroviral vectors
(MR31 and A14) [20,21] and one by a non-integrating, episomal plasmid (BC1) [22]. Our re-
sults show that iPS-OPs reduce cavity formation, scarring and microglial proliferation in a rat
model of moderate contusive SCI. The transplanted iPS-OPs survived up to the end of this
two-month study, and by this time roughly half of the transplanted OPs expressed the mature
oligodendrocyte marker, myelin basic protein (MBP). We further show that transplanted cells
lead to increased remyelination and/or reduced demyelination of axons at the epicenter of inju-
ry, evidence that early intervention using iPS-OPs is feasible for reducing SCI pathology. In ad-
dition, we provide a thorough characterization of the differentiation of iPS-OPs, which has not
been previously reported. This knowledge provides a foundation for future studies whose goals
are to follow or understand how iPS cells differentiate into OPs as well as to study the optimal
cells and media conditions for OP regenerative therapies.
Materials and Methods
Ethics
The experimental design using human iPS cells was approved by the Institutional Stem Cell Re-
search Oversight (ISCRO) committee in the Johns Hopkins University. Use of anonymous
human samples for laboratory research was approved by JHU Institutional Review Board on
Human subjects (ESC-09-05-20-01). This included the acquisition of CD34+ cells for iPS cell
generation from adult patients [20,22]. Fetal brain samples that were used as a reference for
qRT-PCR analysis was supplied by the University of Washington NIH-supported fetal reposi-
tory. In vivo study was carried out in accordance with the guidelines of the Johns Hopkins Uni-
versity for the Care and Use of the Laboratory Animals. The protocol was approved by the
Committee on the Ethics of Animal Experiments with the Protocol Number: RA12M82.
Cell Culture
Three different iPS cell lines were used in this study: BC1 [22], MR31 [21] and A1-4 [20]. The
sources of the iPS cells and the reprogramming methods used are summarized in S1 Table. The
BC1 iPS cell line was generated from adult CD34+ peripheral blood monocytes using an
episomal plasmid (pEB-C5) expressing 5 reprogramming vectors (OCT4, SOX2, KLF4,MYC,
LIN28). Notably, whole-genome sequencing of the BC1 iPS line generated using an episomal
plasmid vector revealed that the vector sequence was undetectable in the genome [22,23]. A1-4
was generated by reprogramming MSCs with retroviruses expressing OCT4, SOX2, KLF4,
MYC, and the high mobility group A1 chromatin remodeling protein, HMGA1 [20]. MR31
was generated from the IMR90 fetal lung fibroblast cell line reprogrammed with retroviruses
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expressing OCT4, SOX2, and KLF4 [23]. iPS cells were cultured and differentiated into OPs as
described previously [19,22,24,25].
Undifferentiated iPS cells were propagated on a mouse embryonic fibroblast (MEF) feeder
layer. All lines were expanded in iPS cell growth media containing DMEM/F12 supplemented
with 20% knockout serum, 5% nonessential amino acids, 5% Glutamax, and 20 ng/ml Fibro-
blast Growth Factor 2 (FGF2) [22]. The iPS cells were differentiated to OPs using methods op-
timized by our laboratory for ES cells [24–26]. First, neural differentiation of undifferentiated
iPS cells was initiated by embryoid body (EB) formation in neurobasal media (Gibco) supple-
mented with Noggin and FGF2 (200 ng/ml and 20 ng/ml, respectively; R&D Systems). EBs
were maintained in ultra-low adhesion tissue culture plate for 15 days. EBs were plated onto
matrigel-coated tissue culture plates in neurobasal media supplemented with FGF2 (20 ng/ml)
for 5 days, leading to differentiation into neural progenitors (NPs). NPs were expanded in this
media for 5–7 days and glial progenitors (GPs) were subsequently induced by adding EGF
(10 ng/ml; R&D Systems). NPs and GPs are distinguished by their morphology, marker ex-
pression and their differentiation capacity. Our laboratory has shown that NPs are able to dif-
ferentiate into neurons and glial cells, while GPs primarily develop into either astrocytes or
oligodendrocytes that are regulated by specific cell culture requirements [26,27]. After 7 days
in GP media, cells are split with 1 mg/ml collagenase and transferred into new plates. OPs were
induced by adding neurobasal medium supplemented with EGF (20 ng/ml) and PDGF-AA
(20 ng/ml; Peprotech) for 25 days. To determine differentiation efficiency among iPS lines,
cells were harvested and RNA extracted for quantitative RT-PCR (qRT-PCR) analysis or cells
placed in chamber slides for immunocytochemistry and protein expression analysis. A subset
of OP cultures were also sorted by O4 expression using magnetically-activated cell sorting
(MACs) and further expanded in culture for use in cell transplantation. O4 is a sulfated galac-
tosylceramide (sulfolipid) synthesized primarily by oligodendrocytes and their progenitors
OPs that has been shown to play a major role in myelin function and stability [28]. O4 expres-
sion is also expressed by NG+ OPs in the human fetal brain [29]. Using this method, we are
able to maintain and expand cultures containing over 98% O4+ OPs that proliferative for up to
six months in culture.
Immunocytochemistrical Characterization and Cell Counting. Cells were plated onto
chamber slides. Before they became confluent, cells were washed twice in phosphate buffered
saline (PBS) and the excess PBS removed. Cells were then fixed in 4% paraformaldehyde (PFA)
in PBS for 10 minutes at room temperature (RT). The fixative solution was removed and cells
were washed twice with PBS for 5 min each. Cells were permeabilized and blocked with PBS so-
lution containing 0.2% (w/v) Triton X-100 (Sigma) and 1% (w/v) bovine serum albumin (BSA;
Sigma) for 5 minutes at room temperature (for cell surface markers this step was omitted as
previously described by [29]. Primary antibody (1:50 dilution, see S2 Table for list of the prima-
ry antibodies) was added after dilution in antibody dilution buffer (PBS with 0.1% (w/v) BSA)
and incubated for 1 hr at RT. Samples were washed three times with PBS for 5 minutes each.
Appropriate secondary antibodies were added (Alexa 488 or Alexa 564 conjugated antibodies,
1:200; Molecular Probes) in antibody dilution buffer and incubated in a humidified dark cham-
ber for 1 hr at RT. Cells were then washed three times with PBS for 5 minutes each. Nuclei
were stained using 4',6-diamidino-2-phenylindole (DAPI) solution (Sigma) for 10 min at RT
in a humidified chamber in the dark. DAPI solution was aspirated and three 0.5 ml PBS rinses
were performed and slides coverslipped. Differentiation of each cell line was performed in trip-
licate. Cells exposed to secondary antibody alone were used as negative controls. The number
of positively stained cells were counted using Metamorph Image Analysis Software (Universal
Imaging, Inc.) from 3 randomly, chosen 10X fields per 24-well cell culture dish and each stain
was repeated in three wells (n = 9).
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Quantitative Real Time-PCR Analysis. Total RNA was isolated from cells stored in RNA-
later (Qiagen) solution using MiniRNeasy kits (Qiagen 74124) and complementary DNA
(cDNA) generated with SuperScript III First-Strand Synthesis System (Invitrogen 18080–051)
reverse transcription kits following the manufacturer instructions. Real-time quantitative poly-
merase chain reaction (qPCR) analyses were performed using ABi7900HT (ABiosystems) in
96 well plates (Abi N801-0560) where each real-time amplification had a template equivalent
to 5 ng of total RNA. Each primer set was tested in at least triplicate across 3 biological repli-
cates. Negative controls included a reverse-transcription-negative control per sample and a no
template control. For these analyses, total RNA extracted from a 92-day old fetal human brain
was used as a positive control. Gene expression and amplification curves were normalized to β-
actin. Taqman Assay-on-Demand designed oligonucleotides were used for the detection of the
following genes (S3 Table). Using the ΔCt method, quantification within the log-linear phase
of the amplification curve acquired for each probe/primer set was normalized to β-actin
and plotted.
Contusive Spinal Cord Injury
All experimental procedures in this study adhered to the guidelines delineated in the Rodent
Survival Surgery guide and approved by the Institutional Animal Care and Use Committees at
the Johns Hopkins University. An ARRIVE Guidelines Checklist for reporting in vivo experi-
ments is provided in Supporting Information (S1 Checklist). A total of 63 rats were used in the
following study, twelve rats were injected with either BC1-, MR31-, or A1-4-derived OPs, PBS
alone or heat-killed BC1-derived OPs and 3 rats with laminectomy alone (sham) were used
for comparisons with electron microscopy. Ten-week-old adult female Lewis rats weighing
~200–220g were used in the study. One of the immediate side-effects of SCI is difficulty urinat-
ing and thus the bladder of these rats must be manually expressed for days immediately after
injury and are thus susceptible to infection. Therefore, this study utilized female rats which are
less suspectible to urinary tract infections under these conditions [30]. All rats were immuno-
compromised three days prior to cell transplantation followed by daily injections of cyclospor-
ine A (10mg/kg/d) until the end of the study, as previously described [24]. Rats (n = 12 per
treatment) were anesthetized with ketamine (7.5 mg/kg; Phoenix Pharmaceutical) and xylazine
(60 mg/kg; Phoenix Pharmaceutical). Laminectomy was performed at thoracic vertebra T8
without opening the dura mater. Injury was produced using a Multicenter Animal Spinal Cord
Injury Study (MASCIS) Impactor, formerly called the NYU-Impactor. The MASCIS impactor
model is a well-established model for studying contusive SCI in rats, and histopathological
changes closely mirror those observed in human SCI [31,32]. This device precisely measures
the movement of a 10 gram rod dropped from 6.25, 12.5, 25.0, or 50.0 mm heights onto a rat
T8-T10 spinal cord after laminectomy to induce Mild (6.25 mm), Moderate (12.5 mm), Severe
(25.0 mm) and Very Severe injury (50 mm) respectively. In this report, the MASCIS impactor
consisting of a 10.0 g weight rod dropped from a 12.5 mm height was utilized to produce a
moderate contusion injury, as previously described [33–37].
Cell Transplantation. Rats were anesthetized 24 hours after injury as described above, and
the injury site on the spinal cord was exposed and the dura excised using a 30-gauge needle.
O4+ OPs cultured in OP-inducing media for 25 days were used as the majority of cells (> than
98%) expressed OP marker O4. Viability was also assessed by sampling a subset of cells with
0.4% trypan blue (Sigma) prior to transplantation and only populations with at least 90% via-
bility were transplanted except for heat-killed controls which had their membranes disrupted
by heating samples at 65°C for 90 minute followed by sonication.
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Twelve rats were randomly selected and injected with either 500,000 live iPS-OPs or heat-
killed iPS-OPs in 2 μL volumes with PBS at a rate of 1 μL/minute into the posterior funiculi of
T8 at a depth of 1.2 mm. This region is known as the injury epicenter. Cells were injected using
a 10 μL Hamilton Gastight syringe with an attached borosillate glass tip (50–100 μm tip diame-
ter) secured to a manual micromanipulator (World Precision Instruments) adjusted with a 80°
tilting base. Briefly, the tip is lowered to a depth of 1.2 mm below the surface of the cord and is
held in place for 2 minutes before the cell injection and 2 minutes after the cell injection. Cells
are delivered under the control of a micro-syringe pump controller (World Precision Instru-
ments). After injection, the dura is closed with a 9–0 suture, the muscles re-apposed, and the
skin closed with sutures. A suture is also placed in the muscle adjacent to the site of injection to
locate the injection site at the time of sacrifice. Sites are monitored for bleeding for the next six
hours and for infections over the next five to seven days. Rats were housed two per cage in a
pathogen-free isolation unit and given subcutaneous injections of isotonic saline (20 ml/kg),
which was administered every morning for 7 days after surgery. The rats’ bladders were ex-
pressed twice daily, and the rats were inspected for weight loss, discomfort, dehydration, and
autophagia, with appropriate veterinary care as needed. Tylenol (100 mg/kg) and gentamicin
(5 mg/kg) were administered every morning for 7 days to minimize pain and potential for in-
fection, respectively. In addition to these study groups, three additional uninjured rats were
employed and served as sham controls (undergoing laminectomies only) to compare the extent
of myelination in the injured SCIs after transplant. These rats were treated under identical con-
ditions following surgery.
Motor Behavior Assessment. The Basso, Beattie, and Bresnahan (BBB) Locomotor Rating
Scale [38,39] was used to validate the motor behavior of each animal before and after injury.
Two well-trained examiners, who were blinded to the experimental group of the animals, eval-
uated and scored the motor behavior of each animal for the left and right sides individually.
The left and right sides were averaged. Scoring was performed on each animal every three days
for the first four weeks, and thereafter performed once per week.
Histological Analyses. Postmortem characterization of transplants was observed up to two
months after transplantation. Rats were deeply anesthetized using isoflurane. Transcardial per-
fusion was performed with DPBS (Gibco) and paraformaldehyde (PFA) solution (4%; 15713-S,
Electron Microscopy Sciences). Spinal cords from twelve rats within each group were randomly
prepared for either frozen sectioning, paraffin embedding or prepared for electron microscopy
and histological assessments were performed by a laboratory technician who was blinded to
the experimental groups. Thus, four rats of each treatment group were either prepared for
cryosection, paraffin sectioning, or embedded for electron microscopy. The spinal cord was
then carefully extracted from the vertebrae column and post-fixed in 4% PFA, followed by 30%
sucrose solution for 24 hours, and last embedded in paraffin or cryopreserved in freezing com-
pound (O.C.T. Tissue-Tek). Frozen tissue was cut in 5 μm sections and prepared for immuno-
histochemistry. For analysis of frozen sections, 30 histological sections, sliced 5μm thick were
analyzed that encompassed the injury epicenter. Immunoflourescent staining with different
antibodies was performed on adjacent slices for each spinal cord. Immunostaining was per-
formed by incubation with 1:100 dilution of primary antibodies (S2 Table) overnight at 4°C in
15% FBS, followed by three rinses in DPBS, and incubated with 1:500 dilution of Alexa 488 and
Alexa 564 secondary antibodies in 15% FBS for 1 hour at room temperature and coverslipped
with DAPI-supplemented mounting media (Vectashield by Vector Labs). DAPI was used to
stain nuclei and to determine the percent of immuno-positive cells. Negative controls included
primary serum and secondary antibody alone. Cords embedded in paraffin were cut in 10 μm
longitudinal sections and stained with either hematoxylin and eosin (H&E) or luxol fast blue
(LFB). Sections encompassing the injury epicenter and surrounding areas of injury were
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selected by consecutively numbering each cut beginning from the dorsal surface. and then every
other slice was stained with either LFB or H&E. The demarcation of glial scarring and cavitation
in controls allowed for easy assessment to determine the boundaries around the epicenter of inju-
ry. This allowed the ability to analyze similar numbers of cuts across treatment groups. To ana-
lyze staining of images across groups were taken at the same exposure time below the level of
saturation and analyzed within the same gray scale. The optical intensities was measured in iden-
tically-sized fields surrounding the injury epicenter and background subtracted from a region on
the same slide surrounding the tissue using Metamorph Image Analysis Software.
Survival and Differentiation of Ops. To determine whether injected human iPS-OPs could
be detected at the end of the study, frozen sections were analyzed using the human cell-specific
marker, human nuclear antigen HNA (Millipore) to determine the number of human cells pres-
ent. To determine the number of OPs that differentiated into mature oligodendrocytes, we
counted the number of HNA/DAPI-positive cells that showed co-localized staining with myelin
basic protein (MBP), a protein specifically expressed by mature oligodendrocytes and not by
OPs. To study how OP transplantation may alter the immune response after SCI, sections were
stained for CD68, (also known as ED-1) to count the number of immune cells (macrophages,
microglia and T-cells) located at the injury epicenter [40]. Astrocyte response and glial scarring
was also quantified by studying the number of GFAP-expressing cells at the epicenter of injury
and by the fluorescence staining intensity around the cavity, as previously described [41].
Tissue Sparing Analysis. Images were analyzed using Metamorph Image Analysis Software,
which allowed the tracing of the spinal cord perimeter and the central cavity for each image
captured, giving the total area for each of these measurements. This analysis was performed on
longitudinal spinal cord sections generated from 8 mm rostral to 8 mm caudal to the injury
epicenter and encompassing the entire width of the spinal cord, as the cavity very rarely ex-
tended beyond this distance. Each cord was analyzed using 10 μm sections stained with hema-
toxylin and eosin and photographed at 16X magnification.
Electron Microscopy. For electron microscopy, spinal cords from 4 rats from each treat-
ment group were processed into small 3 mm3 blocks that surrounded the injury epicenter and
fixed for 1 hour in a mixture of glutaraldehyde (1.5%) and paraformaldehyde (3%), followed by
washing three times in 0.1 M sodium cacodylate and 3 mM CaCl2. Samples were then post-
fixed in potassium ferrocyanide (0.8%) and osmium tetroxide (1%) for 1 hour followed by 3X
washes in 0.1 M sodium cacodylate, and 3 mM CaCl2. Following a brief dH2O rinse, samples
were embedded in Eponate 12 (Pella), and cured at 60°C for 2 days. Spinal cord sections (80
nm in thickness) corresponding to the site of the lesion were cut on a Riechert Ultracut E with
a Diatome diamond knife, collected on formvar-coated 1 X 2 mm2 copper grids, and stained
with uranyl acetate followed by lead citrate. Sections were examined on a Hitachi 7600 trans-
mission electron microscope (TEM) operating at 80 kV.
Myelination was examined on TEM sections at 10000X magnification. Normal myelinated,
demyelinated, and remyelinated axons were counted using the line-sampling technique detailed
by Blight [42]. The average number of normal myelinated, demyelinated, and remyelinated
axons within five 25x25 μm2 areas along the radial line yielded an estimate of the total number of
axons within the injury epicenter, calculated as the number of axons per square millimeter. At
least 10% of the area of injury is encompassed in these calculations. The number of remyelinated
and demyelinated axons was used to determine the oligodendrocyte remyelination efficiency.
Statistical Analysis
All data were expressed as the mean ± SEM. Statistical significance was determined between
treatment groups for cell counting and histological analyses by one-way ANOVA combined
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with Tukey’s posthoc test for comparison between groups. Similarly, significant differences in
BBB scores among groups were also evaluated using a one-way ANOVA followed by a two-
way Student’s t-test assuming equal variances.
Results
Morphological Characterization
We derived OPs from three different human iPS cell lines using our published protocol to gen-
erate OPs from human ES cells [19,24]. We found that all three iPS cell lines exhibited mor-
phologic changes consistent with a transition from the undifferentiated pluripotent stage into
mature oligodendrocytes (Fig. 1). The transition from pluripotency into neuroectoderm was
initiated by formation of embryoid bodies (EBs) in neurabasal media under low attachment
conditions (Fig. 1B). EBs were cultured over a 15-day period and were then plated on matrigel
in neurobasal media supplemented with FGF2 (20 ng/ml). Within 24 hours, cells with a neu-
roectodermal morphology were observed with projections extending outwards from the center
of the EBs (Fig. 1C) indicative of neural progenitors (NPs) in culture. Adding EGF to the
media led the cells to differentiate into glial progenitors (GP) with a bipolar morphology
(Fig. 1D) [43]. At this stage GPs are bipotent and depending on the culturing media can be in-
duced to become either OPs or astrocytes [26]. For transplantation studies, GPs were induced
to differentiate into OPs by the addition of PDGF-AA and the removal of FGF2 from the
media. The resulting cells had the characteristic rounded shape with multiple filopodial-like ex-
tensions (Fig. 1E). Upon removal of PDGF-AA from the culture media and with addition of 40
ng/ml 3,395-Triido-L-thyronine (T3), iPS-OPs demonstrate the ability to generate mature oli-
godendrocytes exhibiting branched morphology with high purity (> than 70%) in unsorted
iPS-OP cultures (Fig. 1F).
Quantitative Gene Expression Analysis
Quantitative real-time PCR (qRT-PCR) analysis was carried out to compare gene expression
profiles in the cells as they progressed from a pluripotent state into OPs. To determine if the
differentiated cells decrease expression of genes associated with pluripotency, mRNA expres-
sion levels of NANOG, OCT4 and SOX2 were analyzed (Fig. 2A-C). We found that the expres-
sion levels of these genes were significantly decreased or undetectable once cells reached the
NP stage. Interestingly, OCT4 expression showed a significant increase in the retrovirally-de-
rived MR31 cell line at the embryoid body stage as compared to undifferentiated cells. These
results suggest a persistence of OCT4 expression in this cell line that remains undifferentiated
under EB conditions. Nonetheless, OCT4 transcript levels decreased after EBs were cultured as
NPs. SOX2 expression also increased in EBs of MR31 and BC1. This is not surprising as SOX2
plays an essential role in early neuroectodermal differentiation [44] in addition to pluripotency.
NANOG expression diminished during OP differentiation in all three lines. Most importantly,
NP cultures from all three lines demonstrated significantly low or undetectable levels of
NANOG, SOX2 and OCT4mRNA transcripts, which is essential in preventing teratoma forma-
tion in vivo.
In addition to downregulating pluripotent genes, NPs also exhibited upregulated markers of
early neural differentiation. For instance, NG2 is expressed in both GPs and OPs found in fetal
and adult spinal cord [29,45]. While undetectable in undifferentiated iPS, low levels were ini-
tially detected in NPs but significant rose 5 days after adding GP induction media in all three
iPS-derived NP lines (Fig. 2D). The increase in NG2 expression was more pronounced for the
MR31 and A1-4 lines (both of which were derived from retroviral delivery of pluripotency fac-
tors), as compared to the BC1 line. However, the differences in NG2 expression in GPs were
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Fig 1. Bright field microscopy images of the various stages of oligodendrocyte differentiation from induced pluripotent stem cells of the BC1 line.
(A) The undifferentiated cells grew in colonies on a mouse embryonic fibroblast feeder layer, (B) Embroid bodies (EBs) were formed by suspending the
undifferentiating cells in culture on ultra-low adherence plates, (C) 15-day EBs were plated on matrigel, leading to the extension of cells of neuroectodermal
lineage. Upon passaging, these neural progenitors grew in a monolayer and were subsequently differentiated to glial progenitors (D) stage. Addition of
platelet derived growth factor-AA (PDGF-AA) to the media led to glial progenitors (GPs) transitioning into the (E) oligodendrocyte progenitor (OP) stage,
displaying a rounded morphology with multiple filopodial extensions. (F) Terminal differentiation was induced by the removal of PDGF-AA, leading to the
appearance of mature oligodendrocytes displaying characteristic branching. Scale bars- A-B: 300 μm, C-F: 80 μm
doi:10.1371/journal.pone.0116933.g001
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transient, as NG2 transcript levels decreased sharply in OPs where mRNA levels were similar
in all three lines (Fig. 2D). To further confirm the identity of the OPs, we examined expression
of genes encoding the myelin oligodendrocyte basic protein (MOBP) and myelin associated
glycoprotein (MAG). Both of these proteins are expressed by myelinating oligodendrocytes
[46,47]. As a positive control, total RNA was extracted from a 92-day old fetal human brain, at
which time PDGFR-α +/O4+ OPs are found in the cortical subventricular zone [29]. We found
thatMAG expression was induced at the OP stage in all three lines (Fig. 2E). In fact, there was
an almost linear increase inMAG expression as the cells progressed from the NP to OP stage in
BC1.MAG expression was also relatively low in the MR31 and A1-4 lines at the GP stage, but
rose sharply during differentiation to the OP stage. TheMOBP transcript levels were also in-
duced in all three OP lines (Fig. 2F), with negligible expression at the NP and GP stages and
up-regulation at the OP stage. Expression ofMAG andMOBP was higher in the control fetal
brain tissue isolated at 13.3 weeks in gestation. This is consistent with other reports that have
shown the presence of myelin marker expression as early as 5 weeks in gestation [29].
Immunocytochemistry and Protein Marker Expression
To corroborate the results for mRNA analyses, we also confirmed protein expression using
immunofluorescence microscopy. Prior studies of oligodendrocyte development show that the
first step in OP development is the differentiation of A2B5+ and NESTIN+ NPs into glial pro-
genitors that express NG2 and PDGFR-α [24]. We also observed robust A2B5 and NESTIN
protein expression in the NPs derived from EBs (Fig. 3A-B). As these cells differentiate into the
GP lineage, they gain NG2 and PDGFR-α protein expression (Fig. 3C-D). Quantitative analysis
was also performed on immunofluorescence images for three independent experiments for
each line at each stage of differentiation. Quantitative analysis showed that>80% of the NPs
were A2B5+ and NESTIN+ (Fig. 3E). In contrast, as expected, proteins associated with more
differentiated OPs such as the RIP antigen, which specifically recognizes 2',3'-cyclic nucleotide
3'-phosphodiesterase in OPs and mature oligodendrocytes [48] as well as O1, MAG and
MOBP, were low or undetected in NPs. In addition to NESTIN and A2B5 expression, greater
than 80% of GPs in all three lines acquired NG2 and PDGFR-α expression (Fig. 3F). Moreover,
some GPs also began expressing O4, RIP and O1 while MAG and MOBP expression was
not detected.
Differentiation into OPs was confirmed by proteins expressed in mid- to late-OP differenti-
ation including RIP, O4, and O1 with downregulation of A2B5 and NESTIN staining. O1 is a
marker of late OP differentiation, while O4 is expressed earlier [19]. These proteins were ex-
pressed in the majority of OPs derived from all three iPS cell lines (Fig. 4A-E). In addition to
markers of early OP differentiation, iPS-OPs also expressed detectable levels of proteins associ-
ated with myelin and are used to identify mature oligodendrocytes that are capable of generat-
ing myelin, such as the MAG and MOBP proteins (Fig. 4F and 4G, respectively). Quantitative
analyses also showed that the number of cells expressing O1 was higher than the number of
OPs expressing O4 from the BC1 line (episomal, non-integrating plasmid delivery or iPS
Fig 2. Plots showingmRNA expression of various developmental markers for all three iPS lines at each stage ofoligodendrocyte differentiation, as
measured using qRT-PCR and normalized to fetal fibroblast controls. Expression of pluripotency associated genes (A)NANOG, (B)Octamer-binding
transcription factor 4 (OCT4) also known as POU5F1 (POU domain, class 5, transcription factor 1) and (C) SRY (sex determining region Y)-box 2 (SOX2) were
undetected in oligodendrocyte progenitors (OPs)whilemarkers indicative of the oligodendrocyte lineage were induced including (D) NG2, (E)Myelin-
associated glycoprotein (MAG), and (F)Myelin-associated oligodendrocytic basic protein (MOBP). Delta CTs were calculated using β-actin as a relative
standard and lines normalized to fetal fibroblast controls. Mean + SEMwere calculated from two independent differentiation experiments for each line and
each gene performed in technical triplicate.Positive control included total RNA from human fetal brain. Abbreviations are Undiff: Undifferentiated iPS cells,
EB: embryoid body, NP: neural progenitor, GP: glial progenitor, OP: oligodendrocyte progenitor.
doi:10.1371/journal.pone.0116933.g002
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factors), which could indicate that BC1 derived iPS-OPs are more efficiently differentiated. In
contrast, the A1-4 and MR31 lines had higher levels of O4, a marker of less differentiated OPs
compared to O1. These proteins were not detected in the NPs or GPs (Fig. 3E). Of note, the
neuronal marker, Neuronal Class III βTubulin (TUJ-1) and the astrocyte marker, glial fibrillary
acidic protein (GFAP), were expressed in less than 1% of the cell population in all three iPS
cells (Fig. 4H and 4I, respectively).
The more differentiated state of the majority of BC1-derived OPs is further supported by re-
duced NP marker expression such as NESTIN and A2B5, which were expressed by nearly
twice as many cells in OP induction media (~60%) in the A1-4 and MR31 lines compared to
BC1 OP cultures (~30%). Furthermore, more cells from the BC1-derived OP cultures express-
ed myelin-associated proteins, MAG and MOBP, and at higher levels compared to MR31 iPS
cells. For instance, MAG was expressed in more than 80% of the BC1 derived-OPs versus less
than 20% in OPs derived from the MR31 line. Similar results were also shown for MOBP,
which was expressed in more than 80% of the BC1 derived-OPs versus 30% of MR31-derived
OPs. The number of the positively stained cells was divided by the total cell number to estimate
the percent of cells that expressed a marker. Each experiment was replicated at least 3 times
from 3 independent differentiation experiments. Despite expression of MAG and MOBP pro-
teins in the iPS-OPs, MBP immunostaining was not detected in any of the iPS-OPs lines. This
funding corroborates what we have previously shown for human ES-derived OPs, where MBP
expression was found exclusively in nonproliferating, terminally-differentiated oligodendro-
cytes with the addition of T3 to the cell culture media [24].
Fig 3. Indirect immunofluorescence detection of neural markers help define the initial stages of oligodendrocyte differentiation from
undifferentiated iPS cells, into neural (NP) and glial (GP) progenitors. (A-D) Photos are of cells derived from BC1 with the differentiated stage
(underlined) and marker analyzed as indicated similar staining patterns were seen in all three lines. Nuclei were stained using DAPI (blue). Most neural
progenitors (NPs) were (A) NESTIN+ and (B) A2B5+ while the majority of glial progenitors (GPs) began expressing early oligodendrocyte progenitor (OP)
markers (C) platelet derived growth factor receptor-α (PDGFR-α) and (D) NG2. Lower panel shows quantification of the indirect immunofluorescence
analyses calculating the percent of labeled cells in all markers. (E) 90% of all cells from each line expressed early markers of the neural lineage including
NESTIN and A2B5. (F) Likewise the number of glial progenitors expressing markers of the early OP lineage such as PDGFR-α and NG2 were also similar
among lines. Differentiation of each cell line was performed in triplicate and the percent of positively stained cells was determined from 3 randomly, chosen
10X fields per 24-well cell culture dish from all three replicates. Values in the graph represent mean ± SEM. * and † denote statistical significance compared
to BC1 and MR31, respectively by ANOVA and Tukey post hoc tests (N = 9, P< 0.001). Scale bars: 100 μm.
doi:10.1371/journal.pone.0116933.g003
Early iPS-Based Intervention Therapy for Spinal Cord Injury
PLOS ONE | DOI:10.1371/journal.pone.0116933 January 30, 2015 12 / 27
Fig 4. Indirect immunofluorescencemarker characterization of oligodendrocyte progenitors derived
from human iPS cells.Nuclei were stained with DAPI (blue). Results show reduced expression of early
markers (A) A2B5 and (B) NG2 and increased protein expression of mid to late oligodendrocyte progenitor
(OP) differentiation markers (C) O4 (D) RIP (E) O1 (F) myelin-associated glycoprotein (MAG) and (G) myelin-
associated oligodendrocytic basic protein (MOBP). Myelin basic protein (MBP) expression was not
detectable by immunostaining. 1% or less of OP cells expressedmarkers of other neural lineages as denoted
by (H) the neuronal maker neuron-specific class III beta-tubulin (TUJ1) and (I) the astrocyte marker glial
fibrillary acidic protein (GFAP). (J) Quantification of the indirect immunofluorescence analyses calculating the
percent of cells expressing a particular marker is shown in the lower panel. A higher percent of cells derived
from BC1 expressed later OPmarkers MAG, MOBP and O1 while fewer cells from the BC1 lines expressed
early neural progenitor (NP) and glial progenitor (GP) markers and early OPmarker O4 compared to MR31
and A1-4. Differentiation of each cell line was performed in triplicate and the percent of positively stained cells
was determined from 3 randomly, chosen 10X fields per 24-well cell culture dish from all three replicates.
Values in the graphs represent mean ± SEM. * and † denote statistical significance compared to BC1 and
MR31, respectively by ANOVA and Tukey post hoc tests (N = 9, P< 0.001). Scale bars: 100 μm.
doi:10.1371/journal.pone.0116933.g004
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OPs Survive and Differentiate after Transplantation
iPS-derived OPs were transplanted into rat spinal cords 24 hours after a moderate contusive
SCI. The BC1 line was used for the in vivo assessments because this line expressed the greatest
amount of late-OP markers compared to the other lines tested. Immunohistological analysis of
spinal cords two months after cell transplantation showed human iPS-OP survival and integra-
tion into the spinal cord without tumor formation (Fig. 5). The site of cell injection can be
Fig 5. Immunohistological characterization in rat spinal cords at the epicenter of injury (asterisks) following transplantation of either (A) heat-
killed iPS-OPs or (B) live iPS-OPs, 24 hours after injury.Human specific anti-nuclei antibody (HNA) staining showed that cells transplanted at the site of
injury could survive, differentiate and express myelin basic protein (MBP, red) in iPS-OPs group, compared to the heat-killed iPS-OPs group. (C) Heat-killed
iPS-OPs treated spinal cords demonstrated more cavitation and higher glial fibrillary acidic protein (GFAP) (green) expression than (D) spinal cords treated
with iPS-OPs. Heat-killed iPS-OPs also expressed less MBP, a mature oligodendrocyte marker, than live iPS-OPs (red). (E) Double immunostaining with
CD68 (expressed by macrophages, microglial, and T cells) and MBP shows more CD68+/MBP+ cells in control animals with morphology indicative of active
macrophages or microglial engulfment of OPs. (F) Spinal cords injected with iPS-OPs had significantly fewer CD68+/MBP+ cells. Tissues shown here were
isolated approximately 2 months after transplantation. DAPI was used to stain rat and human nuclei (blue). Scale bars for A, C, D: 100 μm and B, E, F: 30 μm.
(G) Quantitative image analysis shows that more than 70% of HNA+ cells were differentiated MBP+ oligodendrocytes. Only 4.4 ± 1.5% of grafted cells
express glial fibrillary acidic protein (GFAP), while no HNA+ cells were detected with co-localized staining for neuronal marker neuron-specific class III beta-
tubulin (TUJ1) or NESTIN. Values represent mean ± SEM. * denote statistical significance of humanMBP+ oligodendrocytes and MBP- OPs compared to
either human-derived neural progenitors (Nestin+), neurons (TUJ1+) or astrocytes (GFAP+) and † denotes statistical significance of human HNA+MBP+
compared to HNA+MBP- OPs by Tukey post hoc tests. Tissue slices encompassing the injury epicenter were stained in intervals for each antibody
combination from 4 rats in each treatment group, P< 0.001). (H) Optical density quantification of GFAP staining, which shows significantly higher intensity of
GFAP staining in heat-killed iPS-OP compared with iPS-OPs of both BC1 and MR31 lines. (I) Quantification of the number of CD68+ cells shows significantly
higher CD68+ cells in heat-killed iPS-OPs, indicative of increased inflammation and macrophage activation, compared with iPS-OPs of both BC1 and
MR31 lines. Values in the graphs represent mean ± SEM. * and † denote statistical significance compared to heat-killed iPS-OPs and BC1-OPs, respectively
by Tukey post hoc tests (10 identically numbered tissue slices encompassing the injury epicenter from 4 rats were analyzed for each treatment group,
P< 0.001).
doi:10.1371/journal.pone.0116933.g005
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easily identified as the regions of clustered, transplanted cells in areas with damage to the en-
dogenous tissue. Human cells were confirmed by human anti-nuclei antibody (HNA), which is
not detected in spinal cords injected with heat-killed iPS-OPs (Fig. 5A). In contrast, patches of
cells that co-express HNA (green labeled) and MBP (red labeled) were detected at the injection
site encompassing the injury epicenter in spinal cords transplanted with iPS-OPs (Fig. 5B).
HNA staining indicates survival of the transplanted iPS-OPs while co-localization of HNA and
MBP protein confirms OP differentiation of these cells into mature oligodendrocytes.
Next, we examined the extent of glial scarring by studying the number GFAP+ astrocytes
and the level of staining around the site of injury. Results show increased migration of GFAP+
cells to the site of injury and higher intensity of GFAP staining surrounding cavities in heat-
killed iPS-OP controls (Fig. 5C) compared to iPS-OP treated spinal cords (Fig. 5D). Immune
cells have also been demonstrated in the spinal cords of immunocompromised rats that engulf
transplanted cells and show immunostaining for OP markers [49,50]. To investigate this possi-
bility, we dual-stained sections with MBP and CD68, a marker of multiple types of immune
cells activated in the damaged spinal cord including microglia, macrophages and T cells. Under
normal conditions these cells express basal levels of CD68, which then become elevated when
they are activated [51]. Two months after transplantation, results showed higher numbers of
CD68+ cells in regions treated with heat-killed iPS-OP controls (Fig. 5E) compared to live
iPS-OPs. The presence of CD68+ cells in the spinal cord of control rats after cyclosporine is
consistent with others that show that the same concentration of cyclosporine reduces but not
eliminate CD68+ related activation in this tissue [52]. In Fig. 5F, expression of MBP was seen
in the region of transplantation while only a few CD68 expressing cells could be seen in the
same region of the iPS-OP transplants. Thus, it seems that the transplanted human cells ex-
pressing MBP were not being attacked by the host immune cells. This result may be due in part
to the treatment of cyclosporine used in these rats to inhibit graft rejection. It is interesting that
the same mechanism involved in cyclosporine treatment that prevents the rejection of the
human cell transplants does not prevent the engulfment of endogenous rat oligodendrocytes,
which occurs in the control groups. We observed a much larger number of rounded, foamy-
like microglial shaped cells that were CD68+ and MBP+ in the control groups injected with
heat-killed cells (Fig. 5E). These results suggest that human iPS-OPs may facilitate specific
anti-microglial immune responses in the rat spinal cord after injury.
Quantitation analysis was also performed on a series of dual staining experiments from
cryosections of spinal cords. HNA+ staining was compared with a variety of markers to identify
the differentiated state of the injected iPS-OP BC1 line (Fig. 5G). Staining was also performed
with iPS-OPs derived from the other 2 lines with similar outcomes (data not shown). These
results showed that HNA+ cells that co-labeled with MBP antibody comprised 71.2 ± 10.19%
of the total number of injected HNA+ cells found in the dorsal column. The remaining HNA-
MBP positive cells suggest that endogenous rat OPs also infiltrate the injured region. Some re-
ports have suggested that pluripotent stem cell-derived OPs can differentiate into astrocytes
[53]. Therefore, the expression of the astrocyte marker GFAP was also studied in these sections.
Cells that co-labeled with human nuclei and an astrocyte marker GFAP comprised 4.4 ± 1.5%
of the total number of human nuclei+ cells. The small percentage of GFAP staining in the
HNA+ cells affirms the robustness of this protocol for differentiating stem cells into OPs. On
the other hand, only 0.4 ± 0.1% of transplanted cells co-expressed HNA and the neuronal
marker TUJ-1, and there was no co-expression of HNA and the early neural marker (NESTIN)
detected in our transplanted cells. Therefore, the OPs derived in culture were not a more primi-
tive progenitor, which could generate a large number of neurons or astrocytes after transplan-
tation. Importantly, these results show that a sufficient number of human iPS-derived OPs
survive at least two months after being transplanted 24 hours post-SCI. These unprecedented
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results show the valuable potential of OPs for early interventions to treat SCI, which may en-
hance future outcomes of SCI patients by reducing glial scarring and dampening long-acting
or overactive immune responses that are known to hamper recovery.
OPs Reduce Cavitation after SCI
To study cavitation and morphological changes at the injury epicenter following cell transplan-
tation, longitudinal sections of injured spinal cords were analyzed by H&E staining (Fig. 6A-B)
and electron microscopy. Cavity formation within the gray and white matter surrounding the
epicenter of injury are normally observed in untreated spinal cords following a moderate con-
tusive injury. However, two months after implantation, the cavities manifest differently in spi-
nal cords transplanted with control heat-killed iPS-OPs compared to those transplanted with
the BC1 iPS-derived OPs. The extent of cavitation was 5-fold larger and spread further from
the epicenter in controls (Fig. 6A) compared to iPS-treated spinal cords (Fig. 6B). Longitudinal
sections of the cords were also stained with Luxol fast blue (LFB) to analyze the extent of myeli-
nation after treatment in the areas surrounding the cavitation (Fig. 6C-D). As expected in all
spinal cords, the intensity of LFB staining is greater in the white matter compared to the grey
matter due to the presence of myelinated tracts. Spinal cords injected with heat-killed controls
(Fig. 6C) showed decreased staining compared to those injected with live BC1 iPS-derived OPs
in the white matter tracts (Fig. 6D). This finding suggests remyelination is occurring as a result
of the injected cells. In addition, a greater number of cells with dark blue cytoplasmic staining
could be seen in the control group compared to the treated group (indicated by arrows,
Fig. 6C), which is representative of increased demyelination and macrophage phagocytosis of
disintegrated myelin in the control group [54]. This raises the possibility that iPS-OPs may
provide immunoprotection to the tissue similar to that observed after MSC and neural stem
cell transplantation [55]. Consistent with these findings, the heat-killed control group demon-
strated a significantly higher number of cells with dark cytoplasmic LFB staining compared to
OPs-treated cords as shown in Fig. 6C-D.
OPs Remyelinate Axons after SCI
Increased levels of myelin were demonstrated in rats treated with iPS-derived OPs using trans-
mission electron microscopy (TEM) (Fig. 7A-C). The spinal cord injected with control heat-
killed iPS-OPs showed no evidence of myelination with multiple bare axons or severe disrup-
tion of myelin sheaths encompassing the injury site. On the other hand, spinal cords injected
with BC1-derived iPS-OPs showed evidence of remyelination, where the myelin sheaths are
much thinner with loosely arranged lamellae compared to normal myelination detected in an
the uninjured spinal cord. Quantification of myelination indicated that the number of remyeli-
nated axons was significantly higher in the iPS-OP transplanted group compared with heat-
killed iPS-OP transplanted group (Fig. 7D). iPS-OP transplanted animals also demonstrated
significantly less demyelinated axons compared with heat-killed iPS-OP transplanted animals.
Notably, heat-killed iPS-OPs-transplanted animals contained an average of 60 oligodendrocyte
remyelinated axons per mm2 whereas iPS-OP transplanted animals contained an average of
2760 oligodendrocyte remyelinated axons per mm2, indicating a 46-fold increase in remyelina-
tion in iPS-OP transplanted animals over the heat-killed controls. In addition, more normally
myelinated axons were found at the injury epicenter in iPS-OP transplanted spinal cords
whereas none were visible in controls.
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Motor Behaviorial Analysis
BBB analyses demonstrated in interesting trend in BBB scores among groups (Fig. 8). For in-
stance, motor recovery was initially greater after transplantation in rats either injected with live
or heat-killed iPS-OPs compared to the control group. However, this effect diminished after
the first week and throughout the first month of recovery during which time rats injected with
Fig 6. Hematoxylin and eosin and luxol fast blue stained paraffin sections of spinal cords from
animals subjected to moderate contusive SCI and treated with (A) Heat-killed iPS-OPs or (B) Live,
intact iPS-OPs derived from the BC1 line. As expected for a 12.5 mm contusive injury, cavity formation
was seen in both groups; however, the cavitation in spinal cords treated with iPS-OPs did not form well
defined glial-like scar structures around the cavity periphery, compared to the control group. Thus, controls
showed more pronounced cavitation, which extended further from the epicenter along the central canal. This
indicates that the transplantation of live iPS-OPs into the newly formed cavity 24 hours after injury limited the
normal expected progression of this level of contusive injury. The asterisks indicate the center of the injury
site. Yellow boxes in A and B correspond to adjacent tissue sections stained in C and D, respectively. In
these areas immediately surrounding the center of injury, staining with Luxol Fast Blue (LFB) to identify
myelin showed reduced staining in the control group (C) versus the iPS-OP transplanted spinal cords (D).
Thus, higher levels of LFB in the iPS-OP treated rats may indicate the presence of greater amounts of myelin.
The representative spinal cords shown in (A-D) were harvested approximately 2 months after transplantation.
Dotted lines help delineate regions of white matter (W) and grey matter (G). (E) Area measurements across
groups revealed nearly a 5-fold significant reduction in cavity size in the iPS-OP treated groups compared to
the heat-killed controls. Optical density of LBF, normalized to the optical density of the sham control group,
was calculated for the grey matter (F) and white matter (G) of spinal sections to quantify the amount of myelin
present in each area of the cord. Values in the graphs represent mean ± SEM. * denote statistical
significance compared to heat-killed iPS-OPs by Tukey post hoc tests. For each stain, 5 identically numbered
tissue slices encompassing the injury epicenter from 4 rats were analyzed for each treatment group, P< 0.001.
doi:10.1371/journal.pone.0116933.g006
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PBS alone showed higher scores. This trend was followed by rats injected with iPS-OPs which
showed a significant increase in BBB scores 5 weeks after injection. BBB scores from rats in-
jected with A1-4 derived OPs showed results similar to MR31 (data not shown). Rats injected
with heat-killed iPS-OPs were similar to rats injected with PBS at the end of the study.
Discussion
In this study, we show that OPs can be efficiently derived from human iPS cells from multiple
sources using culture methods similar to those we have previously described [24–26]. We
Fig 7. Transmission electronmicroscopy of transverse sections of the spinal cord showed remyelination of spared axons by BC1-derived iPS-OP
cells after contusive SCI in rats. (A) Normal, endogenous myelination of an uninjured rat spinal cord (laminectomy sham control) as indicated by white
arrows, showing thick and tightly-packed myelin sheaths. (B) Remyelination observed in rats transplanted with BC1-derived OPs, approximately two months
after transplantation. These are sites where oligodendrocytes are detected, as shown in Fig. 4. The relatively thinner and loosely packed myelin sheaths may
be compared with the normal condition in (A), suggesting that this is remyelination by human OPs. (C) Multiple nude axons are visible in rats injected with
heat-killed iPS-OPs, with no observable remyelination, approximately two months after transplant. (D) Quantification shows that transplantation of BC1-
derived OPs resulted in a significant increase in the number of remyelinated axons and reduced demyelinated of axons compared with the heat-killed iPS-OP
group. Values in the graphs represent mean ± SEM. * denote statistical significance compared to heat-killed iPS-OPs by Tukey post hoc tests. Ten images
encompassing the injury epicenter from 4 rats were analyzed for each treatment group (P< 0.001). Magnification (A-C): 10000X.
doi:10.1371/journal.pone.0116933.g007
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generated iPS-OPs from 3 distinct iPS cell lines using 3 different reprogramming strategies.
These lines included the BC1 line that was generated with non-integrating, episomally-mediat-
ed delivery of the reprogramming factors (OCT4 (O), SOX2 (S), KLF4 (K),MYC (M), LIN28)
from adult peripheral blood monocytes and 2 other lines generated from bone marrow-de-
rived, mesenchymal stem cells (A1-4 or HMGA1-OSKM) and fetal lung fibroblasts (MR31) by
retroviral delivery of either HMGA1-OSKM factors or OSK, respectively [20–22]. The varied
reprogramming protocols and origins of cell lines suggest that this approach will be effective in
generating OPs of many diverse iPS cell lines.
As demonstrated by our gene expression analyses, iPS-OPs expressed oligodendrocyte-asso-
ciated markers, including NG2,MOBP, andMAG. Importantly, iPS-OPs lacked the expression
Fig 8. Behavioral assessment 8 weeks followingmoderate contusive injury (12.5mm) and cell transplantation in rats. The average of the Basso,
Beattie, and Bresnahan (BBB) Locomotor Rating Scale (BBB SCORE) for left and right limb movement was evaluated for 55 days following spinal cord injury
in rats injected with either PBS (blue), 500,000 heat-killed iPS-OP cells (green), live BC1-OP (black), or MR31-OP (red) cells 24 hrs after injury. Values in the
graphs represent mean ± SEM of both left and right limbs as there were no significant differences in response between right and left limb scores. Statistical
significance is denoted by a colored asterisk for each cell line with matched color compared to the PBS control group determined by one-way ANOVA
followed by a two-way Student’s t-test assuming equal variances (P< 0.025).
doi:10.1371/journal.pone.0116933.g008
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of iPS/ES cell signature pluripotent genes (OCT4, NANOG, or SOX2), indicating that they had
differentiated along the neural lineage and were no longer pluripotent. Based on prior work
with ES, we distinguished multiple stages of development between EBs and mature oligoden-
drocytes from these 3 iPS lines. These included neural progenitor (NP), glial progenitor (GP)
and OP stages, each of which expresses a specific set of genes and protein markers. Following
differentiation to the NP stage, greater than 80% of the cells expressed the early neural markers
NESTIN and A2B5. At the GP stage, which is generated by the addition of EGF to the growth
media, more than 80% of the cells also expressed NG2 and the PDGFα receptor, in addition to
NESTIN and A2B5. Difference between lines became apparent when differentiation to the OP
stage was induced by the addition of PDGFα to the culture medium. In OPs derived from the
BC1 line, only 30% of cells were positive for the early neural marker NESTIN and more than
60% of cells expressed the OP marker, O1. NESTIN expression in OPs derived from the retro-
viral-derived iPS lines was nearly double at 60% and O1 expression correspondingly lower
than that in BC1 demonstrating their low efficiency at differentiating from their NP and GP
stages into OPs. It will be interesting in future studies to determine whether there is a consis-
tent difference in the ability between non-integrative and integrative approaches for deriving
iPS to differentiation in various subtypes.
While other studies have look at the differentiation efficiency of iPS lines compared to ES
cells [20,21,56], it is not clear whether there are differences in the differentiation efficiency be-
tween iPS cells generated by integrating and non-integrating approaches. Interestingly, studies
have shown that iPS cell lines vary in their differentiation potentials, and it is possible that vec-
tor integration contributes to these differences [57]. No study to date has compared integra-
tion-free iPS and nonintegrated iPS derived OPs. Such a study would require a large number of
iPS-derived lines and hundreds of experimental animals to validate the results. Although con-
firmatory studies are needed, we found that the iPS cells derived using episomal vectors differ-
entiate into OPs more efficiently compared to the iPS cells derived using retroviral vectors.
Furthermore, it is unknown whether the variability of different iPS lines are more depen-
dent on the method of reprogramming than their cell of origin. Indeed others have demon-
strated that iPS differentiation is highly variable compared to ES cells and dependent in part on
their cellular origin. For instance, different lines have demonstrated varying capacities to differ-
entiate into unique cell types [57], and evidence suggests that this is a result of genetic and epi-
genetic differences between the iPS cell lines and their clones [58,59]. Based on these studies,
iPS that are derived from cells of a younger developmental time period may be more “stem-
like”, and therefore may respond to differentiation more efficiently. However, we showed that
BC1 derived from adult blood generated more cells that expressed late-OP markers compared
to both MR31 and A1-4, which are derived from earlier developmental tissue sources (fetal fi-
broblasts and early blood progenitors, respectively). Likewise, MR31 and A1-4 expressed more
immature markers of glial and neural progenitors. These data may suggest that the differentiat-
ing capacity of iPS cells is also influenced by the method of iPS generation. Thus, this finding
demonstrates a new proof-of-principle that given an effective differentiating environment, iPS
cells can differentiate into early glial progenitors with relatively high efficiency regardless of
their mode of generation and original cell of origin. In addition, it emphasizes the importance
of developing effective protocols in eliciting the efficiency of IPS to differentiation intolate
stage OPs for transplantation.
One issue that raises concerns regarding OP transplants is the role of the immune response
at the injured area, such as at the site of spinal cord contusion. It is well known that under nor-
mal conditions during which animals are not immunosuppressed, macrophage infiltration and
glial scarring is increased after SCI [60–62]. This in part is due to the role of astrogliosis, which
contributes to the secondary injury phase of SCI. Reactive astrocytes and microglia are major
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contributors of this process. In response to SCI, astrocytes undergo astrogliosis during which
they become proliferative, hypertrophic and exhibit molecular changes that induce scar and
cavity formation. These reactive astrocytes appear immediately after injury, and scar formation
appears at 3 days [61,62]. By day 3, the initial effects of astrogliosis and scar formation are ben-
eficial for containing the primary injury. However, by day 7 in the rat, the expansion of the
glial scar and hyperactivity of reactive astrocytes ultimately leads to progressive damage of the
spinal cord. Several studies have indicated that the failure of remyelination is correlated with
the presence of this astroglial scar [63–65]. Keirstead et al. demonstrated that progressive astro-
gliosis after SCI is correlated with the failure of myelinogenic transplants to successfully remye-
linate axons if the cells are transplanted after secondary injury has commenced [66]. Our study
showed increased migration of GFAP+ cells to the site of injury and higher intensity of GFAP
staining surrounding cavities in heat-killed iPS-OP controls compared to live iPS-OP treated
animals. This suggests that iPS-OP transplantation 24 h after SCI can attenuate astrogliosis
and reduce inflammation. Interestingly, this finding is consistent with other reports showing
reduced inflammation and astrogliosis following MSC transplantation following SCI [7]. MSCs
as well as other stem cell therapies that reduce inflammation may also suggest that the increases
in motor behavioral recovery seen in rats with a single injection of heat-killed iPS-OPsheat-
killed iPS-OPs are due to secreted factors from these cells [67]. Despite these promising results
after injection, this effect from heat-killed OPs did not facilitate motor behavior or anatomical
recovery in the weeks that followed transplantation. It is possible, however, that multiple injec-
tions during this time period may warrant better outcomes.
Moderate contusive SCIs typically result in tissue loss at the epicenter of injury, producing a
cavity that is essentially devoid of living cells. Cavitation is in part a result of activated astro-
cytes, or reactive astrocytes, and glial macrophages, known as microglia, that are responsible
for the early formation of the glial scar that surrounds the cavity. Glial scarring is important to
prevent further bleeding and destruction to the surrounding spinal cord. However, after activa-
tion, glial cells continue to increase scar formation such that it impedes oligodendrocyte and
axonal regeneration through and around the cavity, impeding recovery [68]. Despite formation
of these cavities, which can consume much of the dorsal area of the cord, the majority of contu-
sive injuries also contain some degree of spared parenchyma across the site of lesion, depen-
dent on the injury severity. These areas consist of neuro-pathways that are anatomically intact
but electrically defunct due to the destruction of oligodendrocytes and consequent axonal de-
myelination. Furthermore, we found that transplantation of live iPS-OP into rat spinal cords
led to a 5-fold reduction in cavity size compared with animals that received heat-killed cells.
Specifically, histological characterization showed neurons and the presence of myelin at the in-
jured site where the OPs were transplanted. This finding indicates that the transplantation of
live iPS-OPs into the area where the normal progression of cavity formation occurs, or 24 h
after injury, limited the normal expected progression of the cavity formation. Most important-
ly, reducing the extent of the glial scar and cavity size is paramount for allowing neural regener-
ation and repair through the site of injury and recovery from SCI. Therefore, iPS-OPs remain a
viable option to pursue for future therapy.
Immunohistochemical analyses provided additional insight into the behavior of the iPS-de-
rived cells when transplanted 24 h after contusive SCI. Staining with human specific antibodies
showed that the injected iPS-OPs survived in the rat spinal cord and could be detected for the
duration of the study, up to two months after transplantation. The cells also efficiently differen-
tiated into oligodendrocytes and distributed over short distances of the spinal cord. H&E-
stained sections of the injury epicenter and injection site revealed the presence of cells or tracts
contiguous with the parenchyma around the injury epicenter. LFB staining showed a greater
presence of myelin encompassing and immediately surrounding the injury epicenter in rats
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treated with iPS-derived OPs compared with heat-killed controls. This could be due to grafted
OPs re-myelinating the axonal tracts proximal to injury, although further studies are needed to
establish this conclusively, as LFB staining also detected endogenous spared myelin. In addi-
tion, only a small percentage of transplanted cells expressed antigenic markers of astrocytes or
other neural lineages. This finding, together with the in vitro immunocytochemical profiling of
the cell populations, indicate effective differentiation of cells to mature oligodendrocytes and a
lack of reversion to a more pluripotent phenotype after transplantation to the injury site.
Motor behavorial assestments were also consistent with the histological data at this time which
showed that rats injected with iPS-OP cells had great motor recovery than rats injected with ei-
ther PBS or heat-killed iPS-OPs. It is interesting that an increase in recovery compared to con-
trols was noted approximately one month after OPs were injected into the spinal cord,
suggesting that this may be the required time frame for their maturation and sufficient remyeli-
nation to detect the earliest benefits of this therapy. What was particularly interesting was the
bimodal distribution in BBB scores or motor improvement from iPS-OPs compared to controls
(the first week and last weeks showing increased scores in the iPS-OP groups) suggesting that
different mechanisms may be contributing to iPS-OP induced recovery. Importantly, the loss
of pluripotency underscores that the transplanted cells did not develop teratomas or cysts in
vivo. Such characteristics are crucial for safe and effective administration of cells as well as tis-
sue repair. These results also lend support to further studies with longer durations to determine
the iPS-OPs efficacy for transplantation.
Remyelination by the implanted cells was confirmed using transmission electron microsco-
py, which showed significantly more myelinated axons in the iPS-OP treated group compared
to the heat-killed iPS-OP control group. Transplantation of iPS-derived OPs 24 h after SCI re-
sulted in a 36-fold increase in oligodendrocyte remyelination of axons throughout the white
matter in the dorsal column after two months, compared with heat-killed iPS-OPs remyelina-
tion in controls. Ensheathment of axons by processes of HNA+-transplanted cells confirmed
that at least some remyelination was performed by transplanted OPs. Several studies have sug-
gested that the difference in myelination seen between stem cell injections and control groups
indicate remyelination from the injected cells [69]. However, other studies, especially those uti-
lizing MSC transplants, have shown that these myelin fraps may indicate remyelination pro-
duced by the rats’ endogenous cells, through trophic factors secreted by iPS-OP transplants
that promote endogenous oligodendrocyte survival [70]. Furthermore, some have shown that
various glial progenitors derived from human and rodents are also able to myelinate after
transplantation [66,71,72]. Thus, we cannot rule out the possibility that our cells may also
actively secrete factors that promote myelination generated by the endogenous tissue. Howev-
er, based on the co-localization of the human specific marker express HNA in the majority of
the cells that also express an essential myelin component and marker of mature OLs, these data
strongly suggest that human iPS-OPs are contributing to the increased levels of myelin detected
by immunostaining, LFB expression, and electron microscopy. Nonetheless, the present study
is the first to show that OPs can also be derived from integration-free human iPS cells and that
these cells at least partially remyelinate injured axons following SCI.
Previous studies have reported the derivation of OPs from murine iPS [73–75] and from
human virally integrated iPS [76,77]. Tokumoto et al. [74]utilized iPS generated from fetal
mouse fibroblasts using retroviruses and showed O4+ early oligodendrocyte progenitors in
vitro, and Czepiel et al. [73] demonstrated myelination from similar cells in the demyelinated
corpus callosum of Shriver-/-mice. A recent study also reported the in vitro differentiation of
oligodendrocytes from retrovirally-derived human iPS cells generated from X-linked adreno-
leukodystrophy patients [76]. Another study reported the differentiation of retrovirally-derived
human iPS cells to OPs and their use in a rat model of optic chiasm demyelination [77]. While
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these cells provide important models for studying oligodendrocyte development and disease,
they cannot be rendered safe for clinical purposes because of the retroviral reprogramming
method used to derive them. To date, no study has shown the survival of a non-integrated iPS
line to generate OPs for treatment of SCI in a rodent model.
Another concern for the clinical use of iPS cells from a recent report in mice that showed
iPS elicit T-cell responses similar that of embryonic stem cells [78]. Interestingly, this same
study showed that iPS generated by non-integrative methods produced significantly lower re-
sponses compared to iPS generated by virus when injected in the same isogenic strain of mice.
Although our study utilized immune-tolerant rats and thus cannot address the mechanisms in-
volved in this type of response, our results do show that BC1 iPS-OPs survive, integrate, and fa-
cilitate myelination within the spinal cord parenchyma in a fashion similar to those generated
with virus. Thus, BC1-derived OPs can provide a suitable source of OPs that would potentially
eliminate this issue in clinical trials.
In conclusion, we show that early transplantation of human iPS derived OPs reduced cavita-
tion and glial scarring up to two months after transplantation. Heat-killed iPS-OP controls and
co-localization of the human specific marker and the mature oligodendrocyte marker MBP
suggest that these effects are dependent on live iPS-OP survival and differentiation at the epi-
center of injury. Moreover, OP differentiation from human stem cell transplantation has been
less efficient compared to mouse models, and we show that their efficiency in vivo is dependent
in part on the media and growth factors employed in its cell culture. For this purpose, we show
the ability to derive in high purity oligodendrocyte progenitors from human iPS lines derived
by a variety of sources including an episomal vector.
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